New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

February 2016

Welcome to the February 2016 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the February issue!

The PharmSource Team

 

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type January 2016 CY 2016
Early Development 92 92
Late Development 89 89
Biologic 64 64
Small Molecule 203 203
Parenteral 86 86
Oral 82 82
New Financings 100 100
Total Drug Leads 407 407
Total Device &
Diagnostic Leads
144 144

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


 

Pipeline Tip

Rock Creek Pharmaceuticals plans to initiate a Phase Ib trial in mid-2016 with modified-release tablet formulations of anatabine citrate in patients diagnosed with mild-to-moderate psoriasis:

  • Therapeutic Area: Dermatology, Anti-inflammatory
  • Dosage Form: Tablet – Controlled release
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of Rock Creek Pharmaceuticals, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
 

Follow the Money: Acceleron Pharma, Inc.

Acceleron Pharma, Inc. is a U.S. public biopharmaceutical company that discovers and develops protein therapies for the treatment of musculoskeletal, metabolic and cancer-related diseases. Acceleron Pharma recently planned to raise $150 million in the completion of a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds for general expenses and to support R&D efforts and clinical trials of its pipeline, including… read on
 

A Closer Look at Medical Devices Approved in 2015

by Judy Nanthavong, Research Analyst

A great feature of the Devices & Diagnostics Edition of the PharmSource Lead Sheet is the option to find devices by medical specialty (therapeutic area). This makes it fast and easy to get the information you need.

The graphs and chart below show pre-market approvals (PMAs) in CY 2015, using data from the PharmSource Lead Sheet together with information from the FDA’s website.

In 2015, our analysts noted an increase in PMA approvals in H1, compared to H1 of 2014. We predicted a steep growth trend, and… read on
 

Lead Generation:
Robots Vs. Humans—And the Winner is…

Occasionally, we hear about companies that use robotic methods to find bio/pharma business leads. We wondered about the quality of information that’s harvested by automatons–and about the coverage that gets missed using this method. There are some potential robot shortcomings of significance:

  1. Coverage of specialty medical conferences (like ASCO, AACR and many others).
    • Many abstracts at these events are embargoed, meaning they’re not made publicly available until they’re presented at the event, where robots are not invited.
    • Even beyond embargoes, having feet-on-the-ground, experienced human representation at medical conferences is likely to deliver more thorough coverage for specialty therapeutic areas.

  2. Robots use logic; humans use expert judgement. Robots are limited by the logic they’re programmed with, and most robots of the caliber being discussed here simply can’t stand up to the practical reasoning and deep understanding that human life science researchers bring—particularly when it comes to searching out corresponding related information that sheds further light.
  3. Incorrectly posted leads frequently occur. Robots don’t know when an erroneous press release posting occurs, but human researchers do, which assures that your time isn’t wasted pursuing false leads. Further, the language used in press releases often is non-specific and doesn’t… read on
  4.  

    Contract Manufacturing Market Opportunities for Antibody Drug Conjugates

    PharmSource’s just-released report, ADC Market Opportunity for CMOs, is an indispensable resource for understanding the technical developments in the antibody drug conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.

    The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company… click here
     

    DCAT Week 2016

    Pharmaceutical Outsourcing CMO Outlook
    PharmSource president Jim Miller will give an overview of the contract dose market for solid dosage and sterile drug products, including key trends, capacity utilization and strategies for supplier differentiation at the Pharmaceutical Outsourcing program on Tuesday, March 15 in the Waldorf Astoria’s Empire Room.

    Join us for DCAT’s 2016 Pharma Industry Outlook
    PharmSource is also pleased to be the program partner for the 2016 Pharma Industry Outlook session, which will be held Monday, March 14 at 1:15 pm in the Waldorf Astoria’s Empire Room. The pharmaceutical industry has experienced favorable signs, a rebound in US pharmaceutical growth and new product innovation. Find out how sustainable these trends are and what role emerging markets will play.
     

    PharmSource Lead Sheet

    The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

    Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

    See for yourself how this resource can be a vital tool for building your brand and growing your market share.

    To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsouce.com / 1-703-383-4903, ext. 112 (ET USA).